Shares of companies that treat everything from Type 2 diabetes to sleep apnea have been sinking since new weight-loss medications skyrocketed.
The weight-loss drugs called GLP-1s are producing some of the market’s biggest losers: investors in companies that treat obesity complications.
Before GLP-1s grabbed center stage, these firms’ sales growth made them some of the highest-valued medical stocks on the market. Now, investors are looking to a future when fewer people develop diabetes and sleep apnea, so they’re dumping the stocks. Obesity seemed untamable, before Novo Nordisk and Lilly found drugs that let people shed 15% to 20% of their weight. Wall Street sees the duo’s sales of the drugs exceeding $40 billion a year by the decade’s end, according to Visible Alpha.
“Those two events really catalyzed this imperceptible, intangible fear and crystallized it,” said J.P. Morgan’s Marcus. “From that point on, it’s just been nonstop GLP-1.” Newsletter Sign-up Insulet declined to discuss GLP-1s with Barron’s, and Tandem didn’t respond to our queries. At the Baird healthcare conference this month, Insulet CEO James Hollingshead told the audience that GLP-1s haven’t affected his company’s 40% year-over-year growth. Patients have trouble getting insurance coverage for GLP-1 drugs, he said, and most stop taking them within two years.
DexCom shares soon resumed their slide. Its recent levels still represent 70 times earnings, so an investor is betting GLP-1s won’t shrink DexCom’s opportunity.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Here are the risks to alcohol and food stocks from Ozempic-like weight loss drugsUnlike the sharp slide in snack stocks, shares of Constellation Brands (STZ) have gained more than 13% year to date.
続きを読む »
Semaglutide Weight Loss Reviews: Before and After PhotosSemaglutide Weight Loss Reviews: Before and After Photos
続きを読む »
This is the best time of day to workout for weight loss: expertsPast studies have looked at the effects of frequency, intensity and duration of exercise, but researchers wanted to determine if time of day has any relevance to the outcome of physical activity.
続きを読む »
Semaglutide 6-Week Belly Ozempic Weight Loss Before and AfterSemaglutide 6-Week Belly Ozempic Weight Loss Before and After
続きを読む »
Eli Lilly sues over US sales of bogus Mounjaro for weight lossEli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the active ingredient in its diabetes drug Mounjaro which is expected to be approved for weight loss later this year.
続きを読む »
Claudia Oshry: It’s ‘so liberating’ to wear arm-baring clothing after Ozempic weight lossLast month, the influencer revealed she had been taking the weight loss drug for nearly a year in an emotional episode of her podcast, “The Toast.”
続きを読む »